Keyphrases
Methylenetetrahydrofolate Reductase Polymorphism
100%
High-dose Methotrexate (HD-MTX)
100%
Antimetabolites
100%
6-mercaptopurine (6-MP)
85%
Maintenance Treatment
57%
Co-treatment
42%
Hematotoxicity
42%
Low Intensity
28%
Dose Reduction
28%
Fever
28%
Acute Lymphoblastic Leukemia
28%
Hepatic Toxicity
28%
Polymorphism
14%
Hospitalization
14%
Treatment Facilities
14%
Methylenetetrahydrofolate Reductase (MTHFR)
14%
A1298C Polymorphism
14%
Pediatric
14%
Neutropenia
14%
Leukemia Patients
14%
Thrombocytopenia
14%
Dose Increase
14%
Total Dose
14%
Cytarabine
14%
Dose Intensity
14%
Single Treatment
14%
Methotrexate Toxicity
14%
Nursing and Health Professions
Drug Megadose
100%
Methotrexate
100%
5,10 Methylenetetrahydrofolate Reductase (FADH2)
100%
Antimetabolite
100%
Mercaptopurine
75%
Maintenance Therapy
50%
Drug Dose Reduction
25%
Acute Lymphoblastic Leukemia
25%
Treatment Centre
12%
Thrombocytopenia
12%
Neutropenia
12%
Drug Dose Increase
12%
Cytarabine
12%
Pharmacology, Toxicology and Pharmaceutical Science
5,10 Methylenetetrahydrofolate Reductase (FADH2)
100%
Methotrexate
100%
Antimetabolite
100%
Mercaptopurine
75%
Acute Lymphoblastic Leukemia
25%
Thrombocytopenia
12%
Neutropenia
12%
Cytarabine
12%
Neuroscience
5,10 Methylenetetrahydrofolate Reductase (FADH2)
100%
Methotrexate
100%
Antimetabolite
100%
Mercaptopurine
75%
Cytarabine
12%